B cell-specific mAb-siRNA conjugates improve experimental myasthenia

Area of Science:

• Immunology
• Neurology
• Pharmacology

Background:

• Myasthenia gravis (MG) is an autoimmune disorder impacting the neuromuscular junction.
• Autoantibodies and complement drive MG pathogenesis, causing muscle weakness.
• Current treatments aim to manage symptoms, but novel therapeutic strategies are needed.

Purpose of the Study:

• To evaluate the efficacy of monoclonal antibody-siRNA conjugates in a mouse model of MG.
• To assess the impact of dual-target conjugates on B cell subsets and autoantibody production.
• To explore the role of PEGylation in enhancing conjugate therapeutic potential.

Main Methods:

• Development and application of monoclonal antibody-siRNA conjugates targeting B cell receptors (CD268 and CD269).
• Assessment of conjugate efficacy in reducing specific B cell populations and acetylcholine receptor (AChR)-specific autoantibodies.
• Evaluation of clinical symptom improvement and functional AChR preservation in a mouse model.

Main Results:

• Optimized dual conjugates significantly reduced CD268 and CD269 expression on B cells.
• Conjugate treatment led to a substantial decrease in AChR-specific autoantibodies.
• PEGylated dual conjugates demonstrated enhanced reduction in autoantibodies and improved clinical MG symptoms.
• Functional acetylcholine receptors were preserved, indicating therapeutic benefit.

Conclusions:

• Monoclonal antibody-siRNA conjugates represent a viable therapeutic strategy for myasthenia gravis.
• Targeting specific B cell subsets with dual-action molecules can effectively reduce autoantibody levels.
• Combination therapies, potentially enhanced by PEGylation, show promise for future MG treatment development.